Table 1.
Patients and tumor characteristics at baseline in the whole cohort and specified by development or not of irAE.
| Variables | Whole Cohort n (%) |
irAE n (%) |
non-irAE n (%) |
|---|---|---|---|
| Age (years ) | |||
| Median (range) | 64 (21–86) | 64 (36–86) | 65 (21–85) |
| Sex | |||
| Male | 118 (76.1) | 52 (74.3) | 66 (77.6) |
| Female | 37 (23.9) | 18 (25.7) | 19 (22.4) |
| Tumor type | |||
| Lung, non-small cell | 76 (49.0) | 42(60) | 34 (40.0) |
| Melanoma | 28 (18.1) | 16 (22.8) | 12 (14.2) |
| Renal | 18 (11.6) | 7(10.0) | 11 (12.9) |
| Head and neck | 17 (11.0) | 2 (2.9) | 15 (17.6) |
| Bladder | 11 (7.1) | 3 (4.3) | 8 (9.4) |
| Others | 5 (3.2) | - | 5 (6.0) |
| ECOG PS | |||
| 0 | 38 (24.5) | 17 (24.3) | 21 (24.7) |
| 1 | 101 (65.2) | 46 (65.7) | 55 (64.7) |
| 2 | 16 (10.3) | 7 (10.0) | 9 (10.6) |
| Treatment Line | |||
| First | 50 (32.3) | 28 (40.0) | 22 (25.9) |
| Second | 91 (58.7) | 37 (52.9) | 54 (63.5) |
| Third | 11 (7.1) | 5 (7.1) | 6 (7.1) |
| Fifth or later | 3 (1.9) | - | 3 (3.6) |
| Type of Immune Checkpoint inhibitor | |||
| Anti-PD-1/PD-L1 | 146 (94.2) | 66 (94.3) | 80 (94.1) |
| Anti-CTLA-4 | 9 (5.8) | 4 (5.7) | 5 (5.9) |
ECOG PS-Eastern Cooperative Oncology Group Performance Status; PD-1-programmed cell death 1; PD-L1-programmed cell death-ligand 1; CTLA-4-cytotoxic T lymphocyte-associated protein 4.